These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 13876510)

  • 21. A study of the antileukemic activity of Rauwolfia alkaloids.
    KRUGER S; ROBISON GA; SCHUELER FW
    Arch Int Pharmacodyn Ther; 1960 Dec; 129():125-30. PubMed ID: 13754579
    [No Abstract]   [Full Text] [Related]  

  • 22. [RESEARCH ON THE CYTO-PHARMACOLOGICAL EFFECTS OF VINCALEUKOBLASTINE (VLB), ALKALOID OF VINCA ROSEA L., ON EMBRYONAL ERYTHROPOIETIC CELLS].
    RONDANELLI R; MAGLIULO E; CULTRERA G; CAVALLI G
    G Ital Chemioter; 1964; 11():108-18. PubMed ID: 14279685
    [No Abstract]   [Full Text] [Related]  

  • 23. Vincaleukoblastine (solid tumors).
    MOORE GE; WATNE AL
    Cancer Chemother Rep; 1961 Jun; 12():192-7. PubMed ID: 13772297
    [No Abstract]   [Full Text] [Related]  

  • 24. Vincaleukoblastine. III. Clinical trial with the oral preparation.
    HODES ME; ROHN RJ; BOND WH; YARDLEY J
    Cancer Chemother Rep; 1961 Oct; 14():129-38. PubMed ID: 13907937
    [No Abstract]   [Full Text] [Related]  

  • 25. Vincaleukoblastine in the treatment of malignant disease.
    WHITELAW DM; TEASDALE JM
    Can Med Assoc J; 1961 Sep; 85(10):584-91. PubMed ID: 13784890
    [No Abstract]   [Full Text] [Related]  

  • 26. [Side-effects on the bone marrow in chemotherapy in cancer].
    PLIESS G
    Verh Dtsch Ges Pathol; 1961; 45():203-7. PubMed ID: 14487213
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic activity of pretazettine on Rauscher leukemia: comparison with the related Amaryllidaceae alkaloids.
    Furusawa E; Irie H; Combs D; Wildman WC
    Chemotherapy; 1980; 26(1):36-45. PubMed ID: 7353439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some biological effects of Vincaleukoblastine, an alkaloid in Vinca rosea Linn in patients with malignant disease.
    WARWICK OH; DARTE JM; BROWN TC; BEER CT; CUTTS JH; NOBLE RL
    Cancer Res; 1960 Aug; 20():1032-40. PubMed ID: 13842983
    [No Abstract]   [Full Text] [Related]  

  • 29. Effective use of a new alkylating agent in doses lethal to bone marrow with protection by tourniquets of marrow in the extremis.
    GOODMAN LE; SCHILLING A; KRAMER SP; ULFOHN A; MILLER S; KRAVITZ S; GABY SD; BAKAL D; WITTEN B; SELIGMAN AM
    Surg Forum; 1961; 12():130-2. PubMed ID: 13900321
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of harringtonine and its allied alkaloids on DNA synthesis in mice bearing leukemias P388. L615 and normal mice (author's transl)].
    Xu YT; Du CZ
    Zhongguo Yao Li Xue Bao; 1981 Dec; 2(4):252-6. PubMed ID: 6462025
    [No Abstract]   [Full Text] [Related]  

  • 31. [On the problem of bone marrow injury by cancerotoxic substances].
    BROCK N; HOHORST HJ
    Klin Wochenschr; 1960 Jan; 38():69-71. PubMed ID: 13804570
    [No Abstract]   [Full Text] [Related]  

  • 32. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
    Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
    Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NEW DEVELOPMENTS IN PLANT DRUGS.
    SCHEINDLIN S
    Am J Pharm Sci Support Public Health; 1964; 136():216-26. PubMed ID: 14239449
    [No Abstract]   [Full Text] [Related]  

  • 35. GROWTH-INHIBITING ACTION OF THE ALKALOIDS OF VINCA ROSEA WITH SPECIAL REFERENCE TO THEIR CAPACITY FOR PREVENTING INTRAVENOUSLY INTRODUCED TUMOR CELLS FROM SETTLING.
    NEMETH L; KELLNER B
    Acta Unio Int Contra Cancrum; 1964; 20():218-20. PubMed ID: 14151890
    [No Abstract]   [Full Text] [Related]  

  • 36. Toxic marrow failure after treatment of carcinoma with cytotoxic drugs.
    CREE IC
    Br Med J; 1960 Nov; 2(5211):1499-500. PubMed ID: 13696350
    [No Abstract]   [Full Text] [Related]  

  • 37. [Studies on the application of anticancer agents before and after the surgical operation, observing the disturbance in tissues, particularly in bone marrow].
    TOMOZIRI R
    Kumamoto Igakkai Zasshi; 1962 Feb; 36():141-72. PubMed ID: 13921821
    [No Abstract]   [Full Text] [Related]  

  • 38. Effective use of a new alkylating agent in children with protection by tourniquets of marrow in the extremities.
    SELIGMAN AM
    Sinai Hosp J (Balt); 1961; 10():91-4. PubMed ID: 13910424
    [No Abstract]   [Full Text] [Related]  

  • 39. THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
    JOHNSON IS; ARMSTRONG JG; GORMAN M; BURNETT JP
    Cancer Res; 1963 Sep; 23():1390-427. PubMed ID: 14070392
    [No Abstract]   [Full Text] [Related]  

  • 40. EFFECT OF HIGH DOSES OF CORTISONE ON BONE MARROW CELL PROLIFERATION IN THE SYRIAN HAMSTER.
    CARDINALI G; CARDINALI G; DECARO BM; HANDLER AH; ABOUL-ENEIN M
    Cancer Res; 1964 Jul; 24():969-72. PubMed ID: 14195349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.